Long-term Outcomes for the Treatment of Paragangliomas in the Upfront, Adjuvant, and Salvage Settings With Stereotactic Radiosurgery and Intensity-modulated Radiotherapy-Reference-Cited by-同舟云学术

Long-term Outcomes for the Treatment of Paragangliomas in the Upfront, Adjuvant, and Salvage Settings With Stereotactic Radiosurgery and Intensity-modulated Radiotherapy

Published:2020-01 Issue:1 Volume:41 Page:133-140
ISSN:1531-7129
Container-title:Otology & Neurotology
language:en
Short-container-title:

Author:

Anderson Joshua L.,Khattab Mohamed H.,Anderson Chelsea,Sherry Alexander D.,Luo Guozhen,Manzoor Nauman,Attia Albert,Netterville James,Cmelak Anthony J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Sensory Systems,Otorhinolaryngology

Reference38 articles.

1. Complex tumors of the glomus jugulare: Criteria, treatment, and outcome;Al-Mefty;J Neurosurg,2002

2. Jugulotympanic paragangliomas: 75 years of evolution in understanding;Forbes;Neurosurg Focus,2012

3. Radiotherapy for benign head and neck paragangliomas: A 45-year experience;Gilbo;Cancer,2014

4. Estimation of growth rate in patients with head and neck paragangliomas influences the treatment proposal;Jansen;Cancer,2000

5. Natural history of cervical paragangliomas: Outcomes of observation of 43 patients;Langerman;Arch Otolaryngol Head Neck Surg,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment for paraganglioma with stereotactic radiotherapy;World Journal of Clinical Cases;2024-06-06

2. Stereotactic radiotherapy for head and neck paragangliomas: How long should we wait for treatment response?;Radiotherapy and Oncology;2024-06

3. Endovascular Embolization as a Stand-Alone Treatment of Head and Neck Paragangliomas with Long-Term Tumor Control;American Journal of Neuroradiology;2024-05-07

4. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants;The Lancet Diabetes & Endocrinology;2023-05

5. Benign Tumors/Premalignant Conditions;Radiation Therapy of Benign Diseases;2023